ArticleInternational journal of hematology2026
Selection of anti-CD38 antibodies for flow cytometric detection of myeloma cells treated with daratumumab or isatuximab.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment with the anti-CD38 therapeutic monoclonal antibodies (mAbs) daratumumab (DARA) and isatuximab (ISA) achieves deep responses in patients with multiple myeloma (MM), often resulting in measurable residual disease (MRD) negativity. CD38 is one of the key surface markers used for flow cytometric MRD assessment in MM; however, DARA is known to interfere with CD38 detection by conventional anti-CD38 mAbs. The impact of ISA on CD38 detection remains unclear. This study aimed to develop optimized methods for accurate detection of CD38 on MM cells by flow cytometry. The anti-CD38-variable heavy chain of heavy chain (VHH) Ab from the JK36 clone enabled clearer detection of surface CD38 on DARA-treated MM cells compared with the anti-CD38 multi-epitope (ME) Abs and anti-CD38 mAbs (T16 and HB7 clones). In contrast, in ISA-treated MM cells, the anti-CD38 mAbs demonstrated superior CD38 detection compared with the anti-CD38 ME Ab and anti-CD38 VHH Ab. These trends were confirmed in primary bone marrow samples from MM patients treated with anti-CD38 therapeutic mAbs. These findings underscore the importance of selecting appropriate anti-CD38 Abs based on treatment history to ensure accurate flow cytometric evaluation of MM cells in patients treated with DARA or ISA.
Indexed as
Identifiers
41975173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.